Martin Shkreli

The analyst's highest conviction call is to short the quantum computing sector, explicitly naming Quantumscape (QS) as a "great short" due to its perceived lack of fundamental value. Similarly, investors are advised to maintain or initiate short positions on Cassava Sciences (SAVA), as it is grouped with other speculative companies expected to decline. Following a failed Phase 2 trial, ImmuneBio (INMB) is viewed with extreme skepticism and its Alzheimer's drug is considered a failure. The company's plan to seek a partner is interpreted as a major red flag that it is abandoning development. The core thesis is to bet against these speculative biotech and tech stocks, which are seen as fundamentally overvalued.

A strong bearish view is held on InMune Bio (INMB) following the failure of its Phase 2 Alzheimer's drug trial to meet its primary goal. The analyst is short the stock, believing it could fall below $1 per share and that the company's positive spin on subgroup data is misleading. Conversely, Sarepta Therapeutics (SRPT) is presented as a long-term value investment for patient investors. While considered a "good value play," the investment in SRPT is expected to be a "slog" and may take time to materialize. Therefore, SRPT should only be considered as one component within a larger, diversified portfolio.

A highly bearish case is presented for Inmune Therapeutics (INMB) following the complete failure of its Alzheimer's drug trial. The drug failed its primary endpoint, and the company's positive spin on subgroup data is a common tactic with a historically low chance of success. With significant safety issues and a weak financial position, the analysis suggests the stock is a strong sell or short candidate. A price target of $0.50 to $1.00 is proposed for INMB. It is expected that the stock will trade below its cash per share, a common outcome for failed biotech companies.

A high-conviction bearish opportunity is identified in Inmune Bio (INMB), with a prediction that the stock could fall 90% following its upcoming clinical data release. This thesis is based on a recent financing deal where INMB sold shares at a massive discount, signaling management's lack of confidence in their own data. Conversely, Sarepta Therapeutics (SRPT) is presented as a major long-term investment holding due to its recovery potential, despite recent underperformance. Other stocks with a strong bearish outlook include Anavex (AVXL), Capricor (CAPR), and IonQ (IONQ), which are viewed as potential short-selling candidates. For investors seeking stability, Intercontinental Exchange (ICE) is highlighted as a high-quality company with a very profitable business model.

A high-conviction short opportunity is identified in InMune Bio (INMB), with expectations of a 90% stock drop following its upcoming Alzheimer's trial data release. Conversely, Sarepta Therapeutics (SRPT) is a strong long-term buy, with its limb-girdle muscular dystrophy (LGMD) gene therapy pipeline viewed as a major, underappreciated catalyst. The analyst is also actively shorting speculative stocks BigBear.ai (BBAI), IonQ (IONQ), and D-Wave Quantum (QBTS), believing they are fundamentally flawed. For a potential long idea, Madrigal Pharmaceuticals (MDGL) was mentioned favorably and is worth further research. These event-driven biotech trades carry significant risk and investors should proceed with caution.

A high-conviction bearish trade is on InMune Bio (INMB) ahead of its imminent Alzheimer's data, with puts at strikes like $5 or $2.50 being a way to position for an expected trial failure. Amgen (AMGN) is a contrarian buy opportunity, as the market over